reports
- Maxim Jacobs
Expanding into immuno-oncology
RXi recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi’s outstanding stock plus milestones. MirImmune had previously licensed RXi’s sd-rxRNA technology in March 2015 and has since selected six lead compounds, which will be used alone or in combination to develop cell therapy to treat cancer. The first cell therapy will likely ...
Update: Samcyprone data at AAD
At the American Academy of Dermatology (AAD) Summer Meeting, data from a pilot study of Samcyprone (diphenylcyclopropenone ointment) in the treatment of common warts was presented. Overall, 38.1% of subjects saw a greater than 50% clearance over seven weeks compared to 6.7% in the placebo arm (p=0.051). On a per-protocol basis, 47.6% saw greater than 50% clearance (p=0.011). A Phase IIa with an improved formulation and 10-week treatment period was initiated in December 2015, with enrolment expec...
Update: Spotlight on cosmetic product development
RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.
Initiation: Delivering on its self-delivering RNAi platform
Over the past year, RXi Pharmaceuticals (RXi) has made significant headway with its pipeline as well as in securing partnerships. Its lead compound RXI-109 is in Phase II in dermatological scarring and is entering the clinic this year in retinal scarring in wet AMD. Phase II dermatology treatment Samcyprone was in-licensed, while a deal was struck with MirImmune for the out-licensing of its proprietary sd-rxRNA technology. We expect the company’s budding pipeline, recently simplified sharehold...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.